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A rise in osmotic concentration (osmolarity) activates the transcription factor Nuclear Factor of Activated T Cells 5 (NFAT5,
also known as Tonicity-responsive Enhancer Binding Protein, TonEBP). This is part of a regulatory mechanism of cells adjusting
to environments of high osmolarity. Under physiological conditions these are particularly important in the kidney. Activation
of NFAT5 results in the modulation of various genes including some which promote inflammation. The osmolarity increases in
patients with renal failure. Additionally, in peritoneal dialysis the cells of the peritoneal cavity are repeatedly exposed to a rise and
fall in osmotic concentrations. Here we review the current information about NFAT5 activation in uremic patients and patients on
peritoneal dialysis. We suggest that high osmolarity promotes injury in the “uremic” milieu, which results in inflammation locally
in the peritoneal membrane, but most likely also in the systemic circulation.
1. Introduction
During the last decades, we have witnessed a rapid growth
of the patient population in need for renal replacement
therapy [1]. Peritoneal dialysis is the most common form of
home dialysis and favoring peritoneal dialysis (PD) as first
strategy termed “PD first” is widely recommended [2]. Yet,
due to various factors such as misconceptions concerning
contraindications to PD, physician training, and apparent
simplicity of HD initiation, but also superior reimbursement
for hemodialysis in some places, this policy has hitherto
not been consequently implemented [3]. “Uremia” has been
described as an inflammatory state, caused by a myriad of
factors accumulating in our patients with progressive loss
of renal function [4]. In addition to this proinflammatory
milieu, in patients on peritoneal dialysis we implant a catheter
and expose them to dialysate. This is a lifesaving therapy but
exposes the patients to additional “stressors.”These include a
foreign body reaction (catheter), glucose toxicity with induc-
tion of advanced glycation endproducts and formation of
glucose degradation products, mechanical stress, changes in
pH, and repeated exposure to a high osmotic concentration.
Over time these “stressors” cause the peritoneal membrane to
deteriorate, which is a major contributor to treatment failure
in patients on PD [5–7]. We became interested in studying
the response of peritoneal cells and biopsies from patients
on PD concerning the response to osmolarity as one “puzzle
stone” which could contribute to the decreased longevity of
the peritoneal membrane.
2. Current View of the Mechanisms Leading to
Peritoneal Fibrosis
Thebiologicalmembrane used in peritoneal dialysis is a com-
plex network of various cell types (e.g., mesothelial cells, peri-
toneal fibroblasts, inflammatory cells, vascular endothelial
cells, and pericytes) and matrix components. The peritoneal
membrane thickens with a progressive accumulation of sub-
mesothelial matrix, which already reaches a significant level
prior to the start of PD [8]. In this “uremic” phase, factors not
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related to the PD procedure already pave the way to the so-
called simple peritoneal fibrosis. Later the clinical decrease in
ultrafiltration capacity is associated with an expansion of the
extracellular matrix (peritoneal fibrosis), formation of small
vessels (neoangiogenesis), vasculopathy, increased number of
lymphatic vessels, and loss of mesothelial cells (denudation)
[9–13].
3. Cellular Responses to Osmotic (Stress)
The osmosensitive transcription factor NFAT5 plays a key
role in the protection of cells against an increase in osmotic
concentration [14]. It regulates the expression of genes which
in part counteract the high osmolarity. Therefore it induces
genes involved in the production and uptake of organic
osmolytes.The role ofNFAT5 in hyperosmolar conditions has
been most intensively studied in kidney cells, as in the renal
medulla cells typically face high concentrations of urea and
sodium chloride [14]. The cellular response to high extracel-
lular solute concentrations is highly conserved in evolution
and not confined to the kidney. Consequently, expression of
NFAT5 has been demonstrated to be ubiquitous throughout
the entire organism.The prototypical reaction of mammalian
cells exposed to high extracellular osmolarity is immediate
shrinkage due to water efflux via aquaporins. Subsequently,
the cell actively increases the concentration of intracellular
organic osmolytes such as taurine, betaine, inositol, sorbitol,
and glycerophosphocholine (GPC) via expression of cer-
tain enzymes such as aldose reductase (AR) or transporter
molecules such as the betaine/GABA transporter (BGT1), the
sodium/myoinositol cotransporter (SLC5A3), or the taurine
transporter (TauT), thus equilibrating intra- and extracellular
osmolar pressure. The above enzymes and transporters have
been shown to be transcriptionally coregulated by NFAT5
(reviewed in [14]).
Certain chronic inflammatory conditions are associated
with local or systemic hyperosmolality. For example, in
patients with diabetes mellitus intermittent hyperglycemia
is associated with increased plasma concentrations of the
proinflammatory cytokines tumor necrosis factor- (TNF-
) 𝛼, Interleukin- (IL-) 6, and IL-18 [15]. In peripheral
blood mononuclear cells from diabetic patients with chronic
microvascular lesions increased NFAT5 DNA binding activ-
ity was demonstrated [16]. IL-1𝛽, IL-6, and IL-18 display
NFAT5 target sequences in their promoter [15], TNF-𝛼 and
LT𝛽 are known target genes of NFAT5 in inflammatory cells
[17], and exposure of human peripheral blood mononuclear
cells to osmotic stress resulted in increased expression of IL-
1 and IL-8 [18]. Consequently, in diabetic patients systemic
hyperosmolality might lead to NFAT5 mediated release of
proinflammatory cytokines.
Osmotic stress also increases nuclear factor-𝜅B (NF-𝜅B)
activity, a key regulator in the induction of inflammatory
responses via the regulation of chemokines, cytokines, and
growth factors. Induction of NF-𝜅B by hyperosmolarity
involves p38 kinase and is independent of NFAT5; however,
NF-𝜅B induced transcription of target genes is significantly
enhanced by binding to NFAT5 [19]. On the other hand, it
is plausible that cytokines such as TNF𝛼 or LT𝛽, which are
released via hyperosmolarity induced NFAT5 activation [17],
lead to secondary activation of the NF-𝜅B pathway. One of
the most extensively studied chemokines is chemokine (C-C
motif) ligand 2 (CCL2), also known as Monocyte Chemoat-
tractant Protein-1 (MCP-1). It regulates the migration and
infiltration of monocytes/macrophages. It can be produced
by a variety of cell types after induction by oxidative stress,
cytokines, growth factors, and hyperosmolarity [20–23]. In
summary there are close interactions between the response
to increased osmotic concentrations and the inflammatory
cascade.
4. Osmotic Concentration in Patients with
Renal Failure and on Dialysis
We became interested in studying NFAT5 in PD patients, as
with the PD solution the peritoneal cavity is continuously
exposed to cycles of a rapid rise and slow fall of osmolarity. An
unexpected finding in our studies was a prominent induction
of NFAT5 in uremic patients [24].
Other authors demonstrated that osmolarity increases
in patients while progressing through the stages of
chronic renal failure [25]. The serum osmolarity averaged
294mosmol/kgH
2
O in patients with normal kidney
function and increased to a mean of 323mosmol/kg H
2
O
in predialytic patients (CKD stage 5). Similar predialysis
osmolalities were measured in dialysis dependent patients
[25]. These results were confirmed in pediatric patients [26].
The underlying mechanisms are not completely understood,
as blood urea does not fully account for the increase in
osmolality. A hypothesis is that the retention of unmeasured
solutes accounts for the increased osmolality as demonstrated
by a rise in the osmolal gap. After a hemodialysis session,
the serum osmolality was found to be reduced, but standard
hemodialysis is not sufficient to return serum osmolality
and osmolal gap back to normal [26, 27]. The chronic
hyperosmolar state might be looked at as an “uremic toxin.”
Exposure of cells to hyperosmolar stress might result in
cell cycle arrest, apoptosis, DNA damage, inhibition of
transcription, and translation and might therefore have
various detrimental effects [14].
5. Osmotic Response of
the Peritoneal Membrane
Osmotic pressure has a significant impact on peritoneal cells,
which was demonstrated by Breborowicz and others, who
showed that exposure of mesothelial cells to hyperosmolar
solutions in vitro leads to acute cell shrinkage [28]. Early
studies on immortalized and primary human peritoneal
mesothelial cells demonstrated that upon incubation with
hyperosmolar solutions (osmolytes: glucose, mannitol, or
NaCl) the matrix metalloproteinase 9 (MMP9) was down-
regulated favoring accumulation of collagen type IV, thereby
potentially promoting the development of peritoneal fibrosis
[29]. The exposure of the peritoneum to hyperosmolar
solutions led to vasodilation in another study [30]. This
effect was hypothesized to be caused by water efflux through
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aquaporin-1 channels of the microvascular endothelium,
which consecutively leads to NO release by the endothelial
cells [31, 32]. Furthermore, induction of apoptosis has been
demonstrated by high osmolarity in mesothelial cells [33].
Lee and others were the first to demonstrate that glucose
induced the expression of the proinflammatory cytokine
CCL2 in human peritoneal mesothelial cells, thereby poten-
tially favoring the influx of proinflammatory cells [21]. The
effects were mediated by glucose itself, since mannitol did
not stimulate CCL2 release. In contrast Matsuo and cowork-
ers used rat peritoneal mesothelial cells (RPMCs) which
responded to hyperosmolar concentrations of glucose (2.5%
(140mM) glucose) with increased transcription and release
of CCL2. The effect was not glucose specific since it was
also observed in cells exposed to the same concentration
of mannitol. This implies that the response was elicited by
hyperosmolarity and not glucose per se. The release of CCL2
was time and concentration dependent. The effects of hyper-
osmolarity (glucose ormannitol) onCCL2mRNA expression
were mediated by protein kinase C (PKC), in part via NF-𝜅B
activation. It could be blocked by micromolar concentrations
of the glucocorticoid prednisolone via inhibition of NF-
𝜅B activation mediated by increased expression of I-𝜅B-𝛼
[22]. The finding that NF-𝜅B activation was only partially
responsible for mediating the downstream effects of PKC
was consistent with earlier findings that also the tyrosine
kinase AP-1 pathway is involved in CCL2 induction elicited
by high glucose concentrations in mesothelial cells [21]. The
finding that the upregulation of CCL2 is mediated by hyper-
osmolarity rather than glucose was supported by Wong and
others who demonstrated that mannitol had similar effects
on human peritoneal mesothelial cells compared to glucose
with respect to CCL2 induction [23]. These findings were
recently recapitulated in immortalized human mesothelial
cells stimulated by hyperosmolar concentrations of glucose,
mannitol, or NaCl [34].
Little or no information is currently available on the role
of peritoneal fibroblasts or the potential cross-talk between
mesothelial cells andmesothelial cells in this complex system.
In summary hyperosmolarity can produce a proinflamma-
tory milieu in mesothelial cells.
6. Potential Role of the Transcription
Factor NFAT5 in Response to Osmotic Stress
in Peritoneal Cells
As described above, peritoneal cells are chronically exposed
to high osmolality during peritoneal dialysis due to the
supraphysiologic osmolality of the dialysis fluids ranging
from 380 to 510mosmol/kg H
2
O, but also to increased serum
osmolality in the predialytic phase in chronic kidney disease.
It has been demonstrated that NFAT5 activation in a
hyperosmotic environment leads to the release of proinflam-
matory mediators [15, 35]. CCL2, especially, was upregulated
in renal tubular epithelial cells upon osmotic stress in an
NFAT5 dependent manner [19, 36]. This has led several
groups to investigate the role of NFAT5 in the response of
peritoneal cells to hyperosmolarity. Ku¨per and colleagues
demonstrated that NFAT5 activity was increased in human
immortalized mesothelial (Met5A) cells upon exposure to
hyperosmolar concentrations of NaCl, mannitol, or glucose
in an osmolality dependent manner [34]. Peak activation of
NFAT5 was reached at 400mosmol/kg H
2
O for glucose and
mannitol and 450mosmol/kg H
2
O for NaCl and decreased
at an osmolality >450mosmol/kg H
2
O. Interestingly, in renal
cells, maximal NFAT5 activation was observed at osmolal-
ities of >500mosmol/kg H
2
O. Knockdown of NFAT5 by
siRNA abrogated CCL2 mRNA and protein upregulation of
these cells stimulated by hyperosmolarity [34]. These results
point to a crucial role of NFAT5 in CCL2 upregulation by
mesothelial cells exposed to osmotic stress. In a further set
of experiments the authors uncovered that the transcription
factor NF-𝜅B was activated under hyperosmotic conditions
and that pharmacologic blockade of NF-𝜅B abolished CCL2
expression. This confirms that NFAT5 and NF-𝜅B cooperate
also in cells of mesothelial origin in the stimulation of
cytokine release upon osmotic stress as has previously been
shown for renal cells ([34], Figure 1). One caveat of this study
is that an immortalized cell line (Met5A) was used and results
were not confirmed in primary human mesothelial cells.
Human peritoneal fibroblasts (HPFBs) have a crucial role
in the pathogenesis of peritoneal fibrosis via release of proin-
flammatory cytokines and synthesis of extracellular matrix
[37]. Our group has thus investigated the response of HPFBs
to hyperosmolar glucose solutions in vitro. Upon exposure
to increasing glucose concentrations in vitro, NFAT5 mRNA
was significantly upregulated in an osmolality dependent
fashion in these cells after six hours. Yet, after 24 and
96 hours no further increase of NFAT5 mRNA could be
observed compared to controls. CCL2 mRNA was only
induced after six hours in the cells exposed to the highest
glucose concentration (125mosmol/kgH
2
O). However, after
96 hours a robust, concentration dependent upregulation
of CCL2 mRNA could be witnessed. Interestingly, CCL2
upregulation occurred at a time point where NFAT5 mRNA
levels were not upregulated any longer compared to controls.
Therefore, there was a significant delay between NFAT5
mRNA induction and upregulation of CCL2, which could
be explained by two scenarios. First, the delay between
NFAT5mRNA induction and upregulation of CCL2might be
explained by the time necessary for the translation of NFAT5
mRNA, synthesis of the protein, and nuclear translocation
of the transcription factor before downstream targets can be
induced. Secondly themore likely scenario is thatCCL2 could
have been induced in an NFAT5 independent fashion [24].
In further experiments, peritoneal biopsies were eval-
uated from uremic patients before the start of peritoneal
dialysis and patients already on peritoneal dialysis and com-
pared to controls. It was observed that in patients not on PD
there was already a thickening of the peritoneal membrane.
This has previously been described by other groups [8, 9].
Unexpectedly, NFAT5 expression was increased not only
in patients on PD, but also in uremic patients not yet on
PD. In healthy controls NFAT5 expression was significantly
lower than in the other two groups. There was no significant
difference in the expression level between uremic patients
and patients on PD. This was true, even when the PD group
was split up into patients with <8 h since the last exposure
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Figure 1: Involvement of osmotic and nonosmotic mechanism in peritoneal fibrosis. (1) Rise in osmolarity stimulates NFAT5 in patients with
“uremia.” Activation of NFAT5 results in a counterregulatory response protecting cells from hyperosmolarity but also induces inflammatory
mediators (e.g., the chemokine CCL2) and growth factors. Additionally antifibrotic factors are downregulated. (2) Exposure to hyperosmolar
dialysate might perpetuate NFAT5 induction. The balance between pro- and antifibrotic factors is shifted towards matrix deposition. Note
that there are osmotic and nonosmotic factors inducing NFAT5 and also direct inducers of CCL2, which increases the complexity of the
system and might lead to several vicious cycles promoting injury. Abbreviations: TNF-𝛼 = tumor necrosis factor 𝛼, Ang II = angiotensin II,
PDGF-BB = platelet derived growth factor BB, TGF-𝛽 = transforming growth factor b, CCL2 = chemokine (C-C motif) ligand 2, MMP9 =
matrixmetalloproteinase 9, AGE = advanced glycation end products, NFAT5 = nuclear factor of activated T cells 5, and Il-1𝛽 = interleukin-1𝛽.
to dialysate and those with >8 h. The stimulus for NFAT5
upregulation in peritoneum of patients prior to the start of
PD is unclear. One possibility is that the increase in plasma
osmolality in patients with preterminal CKD already suffices
to induce NFAT5. Alternatively induction of NFAT5 might
have been induced in a non-osmolality-dependent fashion.
In fact, various circumstances have been described in which
NFAT5 appears to be activated non-osmolality-dependent,
for example, during embryonic development and cancer
metastasis [38, 39]. Also cross-linking of the T cell receptor
in T cells within an isotonic environment resulted in NFAT5
upregulation via calcineurin signaling [40]. In rheumatoid
arthritis NFAT5 expression was shown to be increased in the
synovium and in synovial fibroblast-like cells the cytokines
Il-1𝛽 and TNF-𝛼 strongly induced NFAT5 expression [41].
Finally, Haltermann and others recently demonstrated in
vascular smoothmuscle cells (SMCs) that angiotensin II leads
to nuclear translocation of NFAT5 and downstream gene
transcription. PDGF-BB resulted in increasedNFAT5 protein
expression and SMC proliferation and migration [42].
However, many of the above findings face a similar
problem, that, particularly in the in vivo studies, it cannot be
excluded that a hyperosmolarmicroenvironment contributed
to NFAT5 activation.
Contrary to NFAT5, CCL2 demonstrated a strong induc-
tion in the peritoneum of patients on PD, whereas the CCL2
message was only slightly upregulated in patients prior to PD.
This was confirmed by immunohistochemistry. In the group
prior to PDonly occasional staining inMCswas observed; yet
the MCs and fibroblasts (FBCs) of patients on PD displayed
strong CCL2 immunoreactivity. Finally, while in patients on
PD the peritoneal immunostaining for the NF-𝜅B subunits
p50 and p65 wasmarkedly positivemainly in FBCs, there was
barely immunopositivity in peritoneal FBCs in predialysis
patients and no staining in controls [37].
Taken together, the above data strongly suggests that
osmotic stress during peritoneal dialysis significantly affects
the peritoneum and may contribute to peritoneal inflam-
mation and fibrosis via stimulation of cytokine release from
peritoneal cells. Our data suggests that osmotic stress to the
peritonealmembrane exists even prior to the commencement
of peritoneal dialysis and exposure to hyperosmolar dialysis
fluids in uremic patients as evidenced by upregulation of
NFAT5 mRNA and protein in peritoneal membranes of
predialyis patients. This pathomechanism is fairly conceiv-
able since uremic individuals display significantly increased
serum osmolality as described above. Though speculative, it
is imaginable that serum hyperosmolality in uremic patients
leads to NFAT5 activation within cells of the peritoneal
membrane and the release of proinflammatory and profi-
brotic factors finally leading to thickening of the peritoneal
membrane which has been repeatedly observed in predialytic
patients.
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7. Conclusion
Increased osmolarity is the basis of water elimination in PD.
There is now evidence in uremic patients and PD patients
of an intraperitoneal induction of NFAT5. Osmotic and
nonosmotic trigger might be present in PD, which could
promote an inflammatory response. Also in mesothelial
cells and peritoneal fibroblasts a response to hyperosmolar
dialysate has been illustrated; until now the role of NFAT5
induced by dialysate needs to be shown in vivo.The blockade
ofNFAT5might inhibit the inflammatory response and needs
to be studied in models of peritoneal injury.
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